PROTECTING SYNAPSES TO REVERSE NEURODEGENERATION
5.7 Million Patients Affected in the US
6th Leading Cause of Death in the US
Number of Patients Expected to Triple by 2050
Existing Treatment Options Only Mask Symptoms. No Disease Modifying Therapies Available.
Synapse loss is the main driver of cognition and function loss in Alzheimer’s disease patients during early stages of disease.
Over the past decade, Professor Stephen Strittmatter and founder of Allyx Therapeutics has mapped out the mechanism for synapse loss. Central to this process is the activation of Cellular Prion Protein (PrPC) and the metabotropic glutamate receptor 5 (mGluR5).
Blockade of either protein target is capable of reversing learning and memory deficits while rescuing synapse loss. We believe this approach is capable of delivering a disease modifying approach and preserve cognition in human patients.
Our lead program, ALX-001, is an orally bioavailable small molecule which acts as a silent allosteric modulator (SAM) of mGluR5. ALX-001 has progressed to IND submission and a Phase 1 clinical study is planned in Q1 2021.
Our Founding Team
A world-renowned MD/PhD clinician-scientist and Alzheimer’s disease expert, Steve has served on the faculty of Yale University for twenty-five years. A co-founder of the Yale Program in Cellular Neuroscience, Neurodegeneration and Repair, and Director of the Yale Alzheimer’s Disease Research Center, Steve has a passion for delivering groundbreaking translational science and treatments for Alzheimer’s Disease. Allyx is founded based on discoveries developed over the past decade of work from Steve’s academic laboratory. Steve is an experienced scientist-entrepreneur and founder of ReNetX Bio, a company focused on spinal cord injury.
Founder & CEO
A serial entrepreneur, venture capitalist and former practicing physician, Steve has been on a mission to advance and delivery game innovations in both therapeutics and healthcare delivery. Steve has spent the past 18-years at Canaan Partners as a General Partner. Prior to joining Canaan, Steve founded multiple start-ups, including Radiology Management Sciences (RMS), a company that pioneered managing radiology benefits for health plans where he served as CEO for 6 years. Steve holds an A.B. from Dartmouth College, received his M.A. in the history of science and public policy form Harvard University, and earned his medical degree from the University of Rochester. He trained in radiology at Massachusetts General Hospital/Harvard and in internal medicine at Lenox Hill Hospital/Cornell.
Founder & Director of BD
A scientist and entrepreneur, Tim co-founded Allyx Therapeutics upon completion of the Yale Blavatnik Fellowship for Entrepreneurship. While an inaugural Blavatnik Fellow at Yale, Tim worked within Yale OCR to build and spin out new biotech ventures from the Yale technology portfolio. Tim is a chemical biologist by training and prior to Yale held a scientist role at Ra Pharmaceuticals in Cambridge, MA. Tim holds a B.S. from Boston College and received his Ph.D. in chemistry from Tufts University.
Founder & Advisor
Paul Fonteyne has spent 30+ years in the pharmaceutical industry, retiring at the end of 2018 as Chairman of Boehringer-Ingelheim USA, the US arm of Boehringer-Ingelheim, a private held research driven pharmaceutical company with a rich and growing portfolio of Human Pharmaceuticals, animal health products and biologics contract manufacturing. Paul was with Boehringer-Ingelheim for 15 years in leadership roles both in the US and globally. Prior to Boehringer-Ingelheim, Paul had commercial leadership roles at Merch and Co. Inc. and Abbott Laboratories. Paul holds a MS in Chemical Engineering from the University of Brussels and an MBA from Carnegie Mellon University.